financetom
Business
financetom
/
Business
/
Looking At Upstart Hldgs's Recent Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Looking At Upstart Hldgs's Recent Unusual Options Activity
Dec 27, 2024 9:37 AM

Deep-pocketed investors have adopted a bearish approach towards Upstart Hldgs ( UPST ) , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UPST usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 27 extraordinary options activities for Upstart Hldgs ( UPST ). This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 29% leaning bullish and 70% bearish. Among these notable options, 2 are puts, totaling $100,450, and 25 are calls, amounting to $1,792,031.

Expected Price Movements

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $100.0 for Upstart Hldgs ( UPST ) during the past quarter.

Insights into Volume & Open Interest

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Upstart Hldgs's ( UPST ) options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Upstart Hldgs's ( UPST ) substantial trades, within a strike price spectrum from $30.0 to $100.0 over the preceding 30 days.

Upstart Hldgs Option Activity Analysis: Last 30 Days

Largest Options Trades Observed:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
UPST CALL TRADE BEARISH 12/27/24 $38.55 $36.85 $37.3 $30.00 $167.8K 71 61
UPST CALL TRADE BEARISH 04/17/25 $15.4 $15.2 $15.2 $65.00 $158.0K 378 4
UPST CALL TRADE BULLISH 01/16/26 $42.5 $40.0 $42.5 $35.00 $136.0K 380 32
UPST CALL TRADE BEARISH 04/17/25 $12.55 $12.2 $12.32 $75.00 $123.2K 1.5K 106
UPST CALL TRADE BULLISH 02/21/25 $12.05 $11.8 $11.99 $67.50 $119.9K 129 103

About Upstart Hldgs

Upstart Holdings Inc ( UPST ) provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.

Where Is Upstart Hldgs Standing Right Now?

Trading volume stands at 2,124,883, with UPST's price down by -6.71%, positioned at $67.2.

RSI indicators show the stock to be is currently neutral between overbought and oversold.

Earnings announcement expected in 46 days.

What Analysts Are Saying About Upstart Hldgs

In the last month, 3 experts released ratings on this stock with an average target price of $84.0.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.

* Reflecting concerns, an analyst from JP Morgan lowers its rating to Underweight with a new price target of $57.

* An analyst from Needham has elevated its stance to Buy, setting a new price target at $100.

* An analyst from Redburn Atlantic upgraded its action to Buy with a price target of $95.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Upstart Hldgs ( UPST ) options trades with real-time alerts from Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boeing donating $1 million to Trump presidential inaugural fund, spokesperson says
Boeing donating $1 million to Trump presidential inaugural fund, spokesperson says
Jan 9, 2025
WASHINGTON (Reuters) - Boeing is donating $1 million to U.S. President-elect Donald Trump's inauguration, a spokesperson for the U.S. planemaker said on Thursday. Boeing is joining many major U.S. companies including General Motors, Ford, Microsoft and Meta in donating for the Jan. 20 event. The planemaker previously donated $1 million to the last three presidential inaugurations, including Trump's first in...
Aptose Biosciences Initiates Dosing in Early Study of Acute Myeloid Leukemia Treatment
Aptose Biosciences Initiates Dosing in Early Study of Acute Myeloid Leukemia Treatment
Jan 9, 2025
04:26 PM EST, 01/09/2025 (MT Newswires) -- Aptose Biosciences ( APTO ) dosed the first set of patients in the phase 1/2 study of tuspetinib in combination with venetoclax and azacitidine in patients newly diagnosed with acute myeloid leukemia. Patient enrollment is expected to be 18 to 24 in mid- to late 2025, the company said Thursday in a statement....
Gatos Silver Reports 2024 Production at the Top End of Guidance
Gatos Silver Reports 2024 Production at the Top End of Guidance
Jan 9, 2025
04:24 PM EST, 01/09/2025 (MT Newswires) -- Gatos Silver ( GATO ) after close of trade Thursday reported 2024 production for its 70%-owned Cerro Los Gatos (CLG) mine in Mexico. Silver production was at the top end of the 2024 guidance range and silver equivalent production was slightly above the top end of the 2024 guidance range, according to the...
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma
Jan 9, 2025
04:24 PM EST, 01/09/2025 (MT Newswires) -- IO Biotech ( IOBT ) said Thursday it completed enrollment ahead of schedule in a phase 2 trial of its cancer vaccine candidate IO102-IO103 combined with Merck's ( MRK ) Keytruda to treat people with resectable melanoma or squamous cell carcinoma of the head and neck. Initial data is expected this year, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved